Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma

PURPOSE: Since the introduction of nab-paclitaxel plus gemcitabine (nab-P+GEM) as first-line (1L) treatment for metastatic pancreatic adenocarcinoma (mPDAC), optimal second-line (2L) chemotherapy after progression is unclear. We assessed clinical outcomes of 2L chemotherapy for disease that progress...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Kyoungmin, Bang, Kyunghye, Yoo, Changhoon, Hwang, Inhwan, Jeong, Jae Ho, Chang, Heung-Moon, Oh, Dongwook, Song, Tae Jun, Park, Do Hyun, Lee, Sang Soo, Lee, Sung Koo, Kim, Myung-Hwan, Park, Jin-hong, Kim, Kyu-pyo, Ryoo, Baek-Yeol
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962478/
https://www.ncbi.nlm.nih.gov/pubmed/31291709
http://dx.doi.org/10.4143/crt.2019.190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962478/
https://www.ncbi.nlm.nih.gov/pubmed/31291709
http://dx.doi.org/10.4143/crt.2019.190

Ejemplares similares